Annual Accounts Payable
$15.12 M
-$293.00 K-1.90%
December 31, 2023
Summary
- As of February 8, 2025, FOLD annual accounts payable is $15.12 million, with the most recent change of -$293.00 thousand (-1.90%) on December 31, 2023.
- During the last 3 years, FOLD annual accounts payable has fallen by -$1.94 million (-11.39%).
- FOLD annual accounts payable is now -30.39% below its all-time high of $21.72 million, reached on December 31, 2019.
Performance
FOLD Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Payable
$13.48 M
-$18.58 M-57.95%
September 30, 2024
Summary
- As of February 8, 2025, FOLD quarterly accounts payable is $13.48 million, with the most recent change of -$18.58 million (-57.95%) on September 30, 2024.
- Over the past year, FOLD quarterly accounts payable has dropped by -$9.67 million (-41.78%).
- FOLD quarterly accounts payable is now -83.97% below its all-time high of $84.12 million, reached on June 30, 2019.
Performance
FOLD Quarterly Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Payable Formula
Accounts Payable = Beginning Accounts Payable + Purchases on Credit − Payments to Suppliers
FOLD Accounts Payable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -1.9% | -41.8% |
| 3 y3 years | -11.4% | -41.8% |
| 5 y5 years | +128.9% | -41.8% |
FOLD Accounts Payable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -29.7% | at low | -58.0% | +46.4% |
| 5 y | 5-year | -30.4% | at low | -58.0% | +46.4% |
| alltime | all time | -30.4% | +2752.8% | -84.0% | +3888.5% |
Amicus Therapeutics Accounts Payable History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $13.48 M(-57.9%) |
| Jun 2024 | - | $32.06 M(+248.1%) |
| Mar 2024 | - | $9.21 M(-39.1%) |
| Dec 2023 | $15.12 M(-1.9%) | $15.12 M(-34.7%) |
| Sep 2023 | - | $23.15 M(+71.2%) |
| Jun 2023 | - | $13.52 M(-45.8%) |
| Mar 2023 | - | $24.96 M(+62.0%) |
| Dec 2022 | $15.41 M(-28.4%) | $15.41 M(+28.0%) |
| Sep 2022 | - | $12.05 M(-47.9%) |
| Jun 2022 | - | $23.11 M(+0.9%) |
| Mar 2022 | - | $22.91 M(+6.5%) |
| Dec 2021 | $21.51 M(+26.1%) | $21.51 M(-12.1%) |
| Sep 2021 | - | $24.47 M(+77.8%) |
| Jun 2021 | - | $13.76 M(-14.6%) |
| Mar 2021 | - | $16.11 M(-5.6%) |
| Dec 2020 | $17.06 M(-21.4%) | $17.06 M(+15.6%) |
| Sep 2020 | - | $14.76 M(+3.2%) |
| Jun 2020 | - | $14.31 M(-11.9%) |
| Mar 2020 | - | $16.24 M(-25.2%) |
| Dec 2019 | $21.72 M(+228.8%) | $21.72 M(-73.3%) |
| Sep 2019 | - | $81.47 M(-3.1%) |
| Jun 2019 | - | $84.12 M(+38.8%) |
| Mar 2019 | - | $60.60 M(+817.3%) |
| Dec 2018 | $6.61 M(-16.0%) | $6.61 M(-87.8%) |
| Sep 2018 | - | $54.33 M(+30.6%) |
| Jun 2018 | - | $41.61 M(-4.7%) |
| Mar 2018 | - | $43.68 M(+455.2%) |
| Dec 2017 | $7.87 M | $7.87 M(-85.4%) |
| Sep 2017 | - | $53.71 M(+50.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2017 | - | $35.65 M(-10.1%) |
| Mar 2017 | - | $39.65 M(+207.2%) |
| Dec 2016 | $12.90 M(-21.7%) | $12.90 M(-55.5%) |
| Sep 2016 | - | $29.01 M(+21.8%) |
| Jun 2016 | - | $23.83 M(+5.9%) |
| Mar 2016 | - | $22.50 M(+36.6%) |
| Dec 2015 | $16.48 M(+180.5%) | $16.48 M(-46.1%) |
| Sep 2015 | - | $30.57 M(+80.8%) |
| Jun 2015 | - | $16.90 M(+6.7%) |
| Mar 2015 | - | $15.83 M(+169.5%) |
| Dec 2014 | $5.87 M(+173.7%) | $5.87 M(-48.2%) |
| Sep 2014 | - | $11.33 M(+14.2%) |
| Jun 2014 | - | $9.92 M(+8.2%) |
| Mar 2014 | - | $9.17 M(+327.2%) |
| Dec 2013 | $2.15 M(+1.5%) | $2.15 M(-73.7%) |
| Sep 2013 | - | $8.17 M(-9.4%) |
| Jun 2013 | - | $9.02 M(+40.3%) |
| Mar 2013 | - | $6.43 M(+203.9%) |
| Dec 2012 | $2.12 M(-17.9%) | $2.12 M(-17.9%) |
| Dec 2011 | $2.58 M(+386.0%) | $2.58 M(-73.7%) |
| Sep 2008 | - | $9.80 M(-8.8%) |
| Jun 2008 | - | $10.74 M(+923.3%) |
| Mar 2008 | - | $1.05 M(+98.1%) |
| Dec 2007 | $530.00 K(-55.6%) | $530.00 K(-0.9%) |
| Sep 2007 | - | $535.00 K(+58.3%) |
| Jun 2007 | - | $338.00 K(-80.6%) |
| Mar 2007 | - | $1.74 M(+45.4%) |
| Dec 2006 | $1.20 M(+31.9%) | $1.20 M(+31.9%) |
| Dec 2005 | $906.20 K | $906.20 K |
FAQ
- What is Amicus Therapeutics annual accounts payable?
- What is the all time high annual accounts payable for Amicus Therapeutics?
- What is Amicus Therapeutics annual accounts payable year-on-year change?
- What is Amicus Therapeutics quarterly accounts payable?
- What is the all time high quarterly accounts payable for Amicus Therapeutics?
- What is Amicus Therapeutics quarterly accounts payable year-on-year change?
What is Amicus Therapeutics annual accounts payable?
The current annual accounts payable of FOLD is $15.12 M
What is the all time high annual accounts payable for Amicus Therapeutics?
Amicus Therapeutics all-time high annual accounts payable is $21.72 M
What is Amicus Therapeutics annual accounts payable year-on-year change?
Over the past year, FOLD annual accounts payable has changed by -$293.00 K (-1.90%)
What is Amicus Therapeutics quarterly accounts payable?
The current quarterly accounts payable of FOLD is $13.48 M
What is the all time high quarterly accounts payable for Amicus Therapeutics?
Amicus Therapeutics all-time high quarterly accounts payable is $84.12 M
What is Amicus Therapeutics quarterly accounts payable year-on-year change?
Over the past year, FOLD quarterly accounts payable has changed by -$9.67 M (-41.78%)